Lumos Pharma, Inc. (LUMO) Tops Q2 EPS by 24c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q2 EPS of ($0.93), $0.24 better than the analyst estimate of ($1.17). Revenue for the quarter came in at $490 thousand versus the consensus estimate of $265 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Albemarle names Max Hood as chief accounting officer
• CrowdStrike (CRWD) PT Lowered to $227 at Scotiabank